Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].

Enfermedades infecciosas y microbiologia clinica - 1 May 2008

Muñoz de Benito Rosa M, Arribas López José Ramón

Abstract excerpt

The aim of the PREDICT-1 study was to determine the clinical utility of the pharmacogenetic test identifying HLA-B*5701 to reduce the incidence of hypersensitivity reaction to abacavir, diagnosed clinically and with immunological confirmation, as well as to reduce unwarranted withdrawal of this drug. In the PREDICT-1 study, 1,956 patients were randomized to be screened for HLA-B*5701 before starting abacavir...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Dideoxynucleosides
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HLA-B Antigens

Share to Mass Screening

Share to Pharmacogenetics

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 18680695
DOI: 10.1016/s0213-005x(08)76511-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Prospective validation of a pharmacogenetic test: the PREDICT-1 study].PMID 18680695Read ↗

HLA-B*5701 screening for hypersensitivity to abacavir.Semantic proximity Read ↗

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.Semantic proximity Read ↗

PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse eventsSemantic proximity Read ↗

Successful translation of pharmacogenetics into the clinic: the abacavir example.Semantic proximity Read ↗

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.Semantic proximity Read ↗

[HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].Semantic proximity Read ↗

Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.Semantic proximity Read ↗

Abacavir Pharmacogenetics – From Initial Reports to Standard of CareSemantic proximity Read ↗

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicineSemantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.Semantic proximity Read ↗

Immunopharmacogenomics: Mechanisms of HLA-Associated Drug Reactions.Semantic proximity Read ↗

HLA and pharmacogenetics of drug hypersensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.